Howard Morse

Cooley advised Confluent, a data-streaming platform pioneering a fundamentally new category of data infrastructure that sets data in motion, on its acquisition of WarpStream, an Apache Kafka-compatible data-streaming platform.

Cooley advised Abnormal Security, the leader in AI-native human behavior security, on its $250 million Series D financing at a $5.1 billion valuation.

Cooley advised Nerio Therapeutics, a drug discovery and development company focused on phosphatases, a notoriously difficult class of potentially high-value therapeutic protein targets, on its sale to Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, for up to $1.3 billion.

Cooley advised Harvey, a legal artificial intelligence platform, on its $100 million Series C financing, which brings Harvey to a $1.5 billion valuation.

Cooley advised Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein-coupled receptor (GPCR)-targeted radiopharmaceuticals to treat a broad range of solid tumors, on the formation of a strategic agreement with Eli Lilly to take forward Radionetics’ proprietary GPCR-targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million up-front cash payment. Additionally, Lilly obtained the exclusive right to acquire Radionetics for $1 billion upon conclusion of an exercise period.